---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089684"
form_type: "8-K"
ticker: "XWEL"
cik: "0001410428"
company_name: "XWELL, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:12.971961+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# XWELL Q2 2024 revenue up 14% to $9.3M; net loss narrows to $2.0M from $5.7M

## Summary
- Revenue $9.3M (vs $8.2M Q2 2023); operating loss improved to $1.9M from $4.7M.
- Net loss attributable to XWELL was $2.0M, down from $5.7M in prior year quarter.
- Opened new XpresSpa at Philadelphia airport; plans NYC Penn Station later 2024.
- CDC issued new 3-year biosurveillance RFP; XpresTest bidding; contract value similar to prior.
- Closed $1.4M registered direct offering at $2.18/share; cash & marketable securities $18.4M, no debt.

## SEC filing metadata
- accession: 0001104659-24-089684
- form_type: 8-K
- ticker: XWEL
- cik: 0001410428
- company_name: XWELL, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410428/000110465924089684/0001104659-24-089684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410428/000110465924089684/tm2421605d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089684
- JSON: https://secwatch.observer/filing/0001104659-24-089684.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.